Document is current
Any future updates will be listed below
-
Authors
Fathima, Saubia https://orcid.org/0000-0002-9979-7923
Rokach, Lior https://orcid.org/0000-0002-6956-3341
Ghosoun, Nour
Rezasoltani, Mahsa
Ilyas, Rimal
Alsugair, Ali
McCullough, Kristen https://orcid.org/0000-0003-4252-2619
Abdelmagid, Maymona
Al-Kali, Aref https://orcid.org/0000-0002-0824-3715
Alkhateeb, Hassan B.
Begna, Kebede H. https://orcid.org/0000-0003-2730-8593
Mangaonkar, Abhishek A. https://orcid.org/0000-0003-2458-9887
Matin, Aasiya
Saliba, Antoine N. https://orcid.org/0000-0001-5134-7336
Hefazi Torghabeh, Mehrdad https://orcid.org/0000-0001-8860-3380
Litzow, Mark R.
Hogan, William https://orcid.org/0000-0002-5841-4105
Shah, Mithun https://orcid.org/0000-0002-5359-336X
Patnaik, Mrinal M. https://orcid.org/0000-0001-6998-662X
Pardanani, Animesh
Badar, Talha https://orcid.org/0000-0003-1548-918X
Murthy, Hemant
Foran, James https://orcid.org/0000-0003-1673-1708
Palmer, Jeanne
Punwani, Nathan
Sproat, Lisa
Khera, Nandita
Arana Yi, Cecilia
Tefferi, Ayalew https://orcid.org/0000-0003-4605-3821
Gangat, Naseema https://orcid.org/0000-0002-9104-6172
-
Funding
Funding for this research was provided by:
Advisory board to DISC Medicine and Agios; AT and NG are members of the editorial board for BCJ.
Research funding from Novartis, BMS, Solu Therapeutics and Sanofi
: BeiGene Shanghai, Amgen,Astellas Pharma, Actinium Pharmaceuticals, Syndax, Consultancy;
Research funding from Kura Oncology, Stemline therapeutics, Epigenetix, Solutherapeutics, Polaris and has served on the advisory board for AstraZeneca and SOBI pharmaceuticals
Curio Science, Consultancy
- License Information
-
More Information
Article History
Received: 28 November 2025
Revised: 27 February 2026
Accepted: 25 March 2026
First Online: 6 April 2026
Competing interests
: SF: Nothing to disclose; LR: Nothing to disclose; NoG: Nothing to disclose; MR: Nothing to disclose; RI: Nothing to disclose; AA: Nothing to disclose; KM: Nothing to disclose; MA: Nothing to disclose; AAK: Nothing to disclose; HBA: Nothing to disclose; KHB: Nothing to disclose; AAM: Research funding from Novartis, BMS, Solu Therapeutics and Sanofi; AM: Nothing to disclose; ANS: Nothing to disclose; MHT: Nothing to disclose; MRL: BeiGene Shanghai, Amgen,Astellas Pharma, Actinium Pharmaceuticals, Syndax, Consultancy; WH: Nothing to disclose; MS: Nothing to disclose; MMP: Research funding from Kura Oncology, Stemline therapeutics, Epigenetix, Solutherapeutics, Polaris and has served on the advisory board for AstraZeneca and SOBI pharmaceuticals, AP: Nothing to disclose; TB: Nothing to disclose; HM: Nothing to disclose; JF: Nothing to disclose; JP: Nothing to disclose; NP: Nothing to disclose; LS: Nothing to disclose; NK: Nothing to disclose; CAY: Curio Science, Consultancy; AT: Nothing to disclose; NG: Advisory board to DISC Medicine and Agios; AT and NG are members of the editorial board for BCJ.
: This study was approved by the Institutional Review Board of the Mayo Clinic (IRB protocol number: 12-003574). All methods were performed in accordance with the Declaration of Helsinki, the relevant guidelines, and regulations.
